Cronos Group stock analysis
Want to see TSE:CRON full AI Analyst Report?
Cronos Group (CRON) Stock Price & Analysis
CRON Stock Chart & Stats
- Day’s Range
- CAD 4.35 - CAD 4.47
- 52-Week Range
- CAD 3.26 - CAD 5.47
- Previous Close
- CAD 4.44
- Volume
- N/A
- Average Volume (3M)
- 164.16K
- Market Cap
- CAD 1.61B
- Enterprise Value
- CAD 761.19M
- Total Cash (Recent Filing)
- CAD 741.17M
- Total Debt (Recent Filing)
- CAD 1.21M
- Price to Earnings (P/E)
- 19.0
- Beta
- 1.24
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Profit Growth
The latest quarter demonstrates strong operating momentum across revenue, gross profit, and Adjusted EBITDA, not merely sales growth alone. If product demand and market expansion continue, this broader improvement can support reinvestment, operating leverage, and stronger earnings capacity over the next several quarters.
Leading Branded Product Positions
Sustained leadership in important Canadian product categories indicates meaningful brand recognition and consumer traction. Continued share gains across vapes and edibles can improve distribution relevance, support repeat demand, and provide a durable platform for launching additional differentiated products.
Strong Balance Sheet And Cash Generation
Extremely low leverage gives Cronos substantial financial flexibility to fund operations, product development, and expansion without relying heavily on borrowing. Positive operating and free cash flow further strengthen resilience and provide internal funding capacity if the current improvement persists.
Bears Say
Earnings Consistency Remains Unproven
The recent profitability inflection is encouraging, but the multi-year record shows that earnings have not yet demonstrated consistency through changing market conditions. Prior losses and uneven results increase the risk that current margins may normalize or weaken if demand, pricing, or product mix changes.
Price Compression And Regulatory Constraints
As European cannabis supply expands and markets mature, price compression could reduce revenue quality and constrain gross margins even when volumes grow. Netherlands-specific restrictions on formats, wholesale activity, and approvals may also slow the conversion of expansion opportunities into durable earnings.
Lumpy And Seasonal International Sales
Seasonal purchasing patterns and permit-dependent shipments make quarterly revenue and margin performance less predictable. This variability can complicate capacity planning, obscure underlying demand trends, and create periods where reported results lag the company’s longer-term international growth opportunity.
Cronos Group News
CRON FAQ
What was Cronos Group’s price range in the past 12 months?
What is Cronos Group’s market cap?
When is Cronos Group’s upcoming earnings report date?
How were Cronos Group’s earnings last quarter?
Is Cronos Group overvalued?
Does Cronos Group pay dividends?
What is Cronos Group’s EPS estimate?
How many shares outstanding does Cronos Group have?
What happened to Cronos Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cronos Group?
What is the TipRanks Smart Score and how is it calculated?
Cronos Group Stock Smart Score
Company Description
Cronos Group
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Michael Ryan Gorenstein
- Employees
- 610
- Website
- www.thecronosgroup.com
- Address
- 4491 Concession Road 12, Stayner, ON, L0M 1S0, CA
Cronos Group (CRON) Earnings & Revenues
CRON Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Cronos reported substantial year-over-year growth and records across net revenue, gross profit, and Adjusted EBITDA, supported by strong performance in Israel, Canada, Germany, and other international markets. The company also highlighted brand share gains, product innovation, a strong cash position, and the completed CanAdelaar acquisition. The main challenges were seasonal Canadian softness, lumpy international shipment timing, price compression, tight Canadian flower supply, higher operating expenses, and regulatory and permitting constraints in the Netherlands, but these did not outweigh the reported operating momentum.
View all TSE:CRON earnings summariesCRON Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 12 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |











